Are HER2 and TOP2A useful as prognostic or predictive biomarkers for anthracycline-based adjuvant chemotherapy for breast cancer?

Journal of Clinical Oncology

Volumn 27, Issue 24, 2009, Pages 3875-3876

  Pritchard, Kathleen I ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TUMOR MARKER; DNA BINDING PROTEIN; DNA TOPOISOMERASE II ALPHA; HER2 PROTEIN, HUMAN; TUMOR ANTIGEN;

ADJUVANT CHEMOTHERAPY; BREAST CANCER; CANCER CHEMOTHERAPY; CHROMOSOME 17; EDITORIAL; GENE AMPLIFICATION; GENE DELETION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HUMAN; PRIORITY JOURNAL; PROGNOSIS; BREAST TUMOR; FEMALE; GENETICS; MORTALITY; NOTE; PHYSIOLOGY;

ANTHRACYCLINES; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; FEMALE; HUMANS; PROGNOSIS; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL;

EID: 69849093714     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.22.8361     Document Type: Editorial

References (17)

1. Paik S, Bryant J, Park C, et al: ErbB-2 and response to doxorubicin in patients with axillary lymph node positive, hormone receptor negative breast cancer. J Natl Cancer Inst 90:1361-1370, 1998
2. Paik S, Bryant J, Tan-Chiu E, et al: HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. J Nat C Inst 92:1991-1998, 2000
3. Di Leo A, Chan S, Paesmans M, et al: HER2/neu as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel. Br Cancer Res Treat 86:197-206, 2005
4. Pritchard KI, Shepherd LE, O'Malley FP, et al: HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 354:2103-2111, 2006
5. Dhesy-Thind B, Pritchard K, Messersmith H, et al: HER2/ neu in systemic therapy for women with breast cancer: A systematic review. Breast Cancer Res Treat 109:209-229, 2008
6. Gennari A, Sormani MP, Pronzato P, et al: HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: A pooled analysis of randomized trials. J Natl Cancer Inst 100:14-20, 2008
7. De Laurentiis M, Arpino G, Massarelli E, et al: A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clinical Cancer Res 11:4741-4748, 2005
8. Poole CJ, Earl H, Hiller L, et al: Epirubicin and cyclophosphamide, methotrexate, and fluourouracil as adjuvant therapy for early breast cancer. N Engl J Med 355:1851-1862, 2006
9. Bartlett JMS, Munro A, Cameron DA, et al: Type I receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial. J Clin Oncol 26:5027-5035, 2008
10. Di Leo A, Isola J, Piette F, et al: A meta-analysis of phase III trials evaluating the predictive value of HER2 and topoisomerase II alpha in early breast cancer patients treated with CMF or anthracycline-based adjuvant therapy. Br Cancer Res Treat 107:214, 2008 (abstr 705)
11. Knoop AS, Knudsen H, Balslev E, et al: Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin and fluorouracil: Danish Breast Cancer Cooperative Group. J Clin Oncol 23:7483-7490, 2005
12. O'Malley F, Chia S, Tu D, et al: Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. J Natl Cancer Inst 101:644-650, 2009
13. Slamon DJ, Mackey J, Crown J, et al: Role of anthracycline-based therapy in the adjuvant treatment of breast cancer: Efficacy analyses determined by molecular subtypes of the disease. Br Cancer Res Treat 106:112, 2007 (abstr 13)
14. Tubbs R, Barlow W, Budd T, et al: Outcome of early stage breast cancer patients treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status. J Clin Oncol 27:3881-3886, 2009
15. Hayes DF: Prognostic and predictive factors for breast cancer: Translating technology to oncology. J Clin Oncol 23:1596-1597, 2005
16. Hayes DF: Prognostic and predictive factors revisited. The Breast 14:493-499, 2005
17. Bartlett JMS, Munro A, Dunn J, et al: Chromosome 17 polysomy (CH17) as a predictor of anthracycline response: Emerging evidence from the UK NEAT adjuvant breast cancer trial. Br Cancer Res Treat 107:103, 2008 (abstr 45)